Janine Schuurman
Commit Biologics has appointed Janine Schuurman to its board
Commit Biologics has announced the appointment of Janine Schuurman to its Board of Directors.
Janine is a widely recognised scientific leader with over 25 years’ experience in antibody research, discovery and development.
She is the co-inventor of several FDA-approved drugs, including amivantamab and epcoritamab.
Janine also played a key role in the development of antibody platform technologies while at Genmab, such as DuoBody and HexaBody, and rose to become Senior Vice President, Head of Antibody Research and Development.
A renowned speaker at scientific conferences, Janine is currently President of The Antibody Society, a highly regarded non-profit supporting antibody-related research and development.
Krishna Polu, MD, Chief Executive Officer of Commit Biologics, said: “Janine brings a wealth of knowledge and experience that will greatly benefit Commit – both in terms of the science of antibody research and development, and in the practical know-how of building teams, pipelines and partnerships that is so essential to achieving drug approvals success.”
About Author
